logo-loader
viewPropanc Biopharma, Inc.

Propanc Biopharma appoints Ralf Brandt to scientific advisory board as it develops cancer patent

Propanc Biopharma Inc (OTCMKTS:PPCB) chief executive officer James Nathanielsz speaks to Procative Investors about the company's recent appointment of Dr Ralf Brandt to its scientific advisory board.
 
The company is developing patents for cancer treatment that focuses on solid tumours, using its lead product PRP, and recently received a notice of allowance for its US patent formula. 
 
Nathanielsz says: "This is quite an exciting development because in the US, biologicals, especially ones that are naturally derived, are quite often hard to patent.
 
"We've been able to identify claims that we believe were novel and inventive and the US Patent and Trademark Office agreed - this is probably the highest level of protection needed in the biggest market in the world."

Quick facts: Propanc Biopharma, Inc.

Price: 0.0084 USD

OTCMKTS:PPCB
Market: OTCQB
Market Cap: $395.53 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Perseus Mining acquiring fellow West African gold company Exore Resources

Perseus Mining Limited (ASX:PRU) (TSE:PRU) (OTCMKTS:PMNXF) and the board of Exore Resources Ltd (ASX:ERX) (OTCMKTS:NLIOF) have agreed to an arrangement whereby Perseus will acquire 100% of Exore by way of a scheme of arrangement, subject to shareholder approval and court approval. Perseus...

16 minutes ago

2 min read